培美替尼治疗胆管癌的效果怎么样

Pemetinib has a significant effect in the treatment of cholangiocarcinoma. It exerts anti-tumor activity by inhibiting fibroblast growth factor receptors (FGFRs), which can prolong the survival period and improve the quality of life of patients. Results from the phase II FIGHT-202 trial, which enrolled 107 patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, showed that of 38 patients who responded, 24 (63%) had a response that lasted at least six months and 18 (<>%) had a response that lasted at least a year. Treatment was generally safe and well tolerated.

In an ongoing multicenter, single-arm, phase II study (NCT04256980), adult patients with locally advanced or metastatic cholangiocarcinoma harboring centrally confirmed FGFR2 fusions or rearrangements and who have received ≥1 prior systemic therapy receive 13.5 mg orally once daily (3-week cycles; 2 weeks, 1 week off) until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was objective response rate (ORR) as assessed by an independent radiology review committee.

Results: A total of 31 patients were enrolled, with a median follow-up time of 5.1 months. Among the 30 patients with FGFR2 fusion or rearrangement evaluated for efficacy, 15 patients achieved partial response (ORR, 50.0%); 15 patients had stable disease, and the disease control rate was 100%. The median time to response was 1.4 months, the median duration of response was not reached, and the median progression-free survival was 6.3 months.

Eight of 31 patients (25.8%) experienced grade ≥3 treatment-emergent adverse events. Hyperphosphatemia, hypophosphatemia, nail toxicity, and eye disease were mostly

Conclusions: Encouraging antitumor activity and favorable safety profile support the use of pemetinib in previously treated Chinese patients with cholangiocarcinoma and FGFR2 rearrangements.

Common side effects of pemetinib include diarrhea, nausea, taste change, vomiting, loss of appetite, weight loss, constipation, stomach pain, aphtha, onychomycosis, hair loss, headache, fatigue, joint pain, dysuria, limb or joint swelling and pain, muscle spasm, numbness or dry mouth, etc. The patient's side effects are related to their own constitution and condition.

Recommended related articles:

References

Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, Bao LQ, Zhao HT, Zhao H, Feng XL, Zhang BX, Peng T, Zhang YB, Li XC, Yu HS, Cao Y, Liu LX, Zhang T, Wang WL, Ran JH, Liu YB, Gong W, Chen MX, Cao L, Luo Y, Wang Y, Zhou H, Yang GH, Fan J, Zhou J. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study. Cancer Med. 2023 Feb;12(4):4137-4146. doi: 10.1002/cam4.5273. Epub 2022 Sep 20. PMID: 36127767; PMCID: PMC9972033.